Online Registration is Open!
Register by Friday, March 20 to Save up to $800 off standard rates.
Add to Outlook Calendar
THE Industry Meeting Place to Exchange Real-World Solutions to Improve Speed, Cost and Quality
Conference: October 26-29, 2015 · Exhibition: October 17-19, 2015 ·
Cell Culture & Upstream Processing Track Value:
"BPI was a great, great conference. I enjoyed the presentations, discussions and networking." - Saeko Tanaka, Chugai Pharmaceutical Co., Ltd, Japan
Process development scientists, engineers and technical experts share their recent achievements in reducing timelines and COGs while increasing efficiency and productivity through implementation of disruptive approaches and technologies across all stages of cell culture.
Cell Culture & Upstream Processing Track Coverage:
Recovery & Purification Track Value:
"BPI is a great opportunity to meet leaders, and innovators in this industry." - Holzer Margit, VP R&D and Technology, Novasep
Building on the momentum being gained from the innovation of methodologies, materials science and technologies, companies will describe progress being made to optimize efficiencies, process design and flexibility in downstream processing for an emerging wave of antibodies and novel modalities.
Recovery & Purification Track Coverage:
Manufacturing Strategy Track Value:
"This conference is always a great opportunity to get a very comprehensive overview on new trends in biologics process development, manufacturing aspects and new trends in the biologics business." - Wolfgang Noe, Ph.D., Vice President, Bioprocess Development, Biogen Idec
Biomanufacturing experts share strategies to maximize efficiencies and cost savings across your manufacturing network through implementation of disruptive technologies, operational excellence and new facility concepts. Learn how to develop your manufacturing infrastructure so you can remain flexible to the production needs of a diverse pipeline of novel biologic molecules in a multiproduct environment.
Manufacturing Strategy Track Coverage:
Analytical, Formulation and Quality Track Value:
"These BPI conferences bring together established industry leaders and upstart newcomers, scientists working on the problems that will define the future of our industry and analysts tackling the issues that have been with us for decades. This is the best place to connect with people expanding what it means to work in biotech and bioprocessing. Without this, everyone would be working in the dark." - Mitchell Fraller, Associate, AlphaVax
Thought-leaders in the field help you to stay abreast of emerging analytical tools and formulation strategies for mAb, non-mAb and next generation biotherapeutics. Learn about the impact of increasing quality expectations for your products and processes so you can optimize your analytical and formulation strategy and reduce quality risk across the product lifecycle.
Analytical, Formulation and Quality Track Coverage:
Drug Product Strategies and Technologies Track Value:
"A great mix of practical and strategic themes, with good opportunities for networking with relevant industry players." - Sancha Salgueiro, Manager, Novozymes
Explore the technologies, strategies and solutions involved in moving from API (drug substance) to finished drug product ready for human use. Case studies and real world experiences will be presented to highlight potential pitfalls and challenges for a variety of different products. An evaluation of emerging technologies and creative drug product solutions will also be presented.
Drug Product Strategies and Technologies Track Coverage:
Early Stage Biologics and Early Stage Companies Track Value:
"A must-attend annual conference for [the] biopharmaceutical industry!" - Jinyou Zhang, Ph.D., Associate VP, Process Development & Manufacturing, Immunomedics, Inc.
Learn how to accelerate the transition from biologics discovery to IND and beyond by implementing these key strategies and critical development activities. Learn from experts who will help guide you through the steps you need to take to help you reduce your risk, development timeline and costs, while maximizing the chance of success for your new products.
Early Stage Biologics and Early Stage Companies Track Coverage: